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Abstract
Background and Aims Steroid resistance presents an ad-
ministration difficulty in inflammatory bowel disease
(IBD). The reason of steroid resistance is still unclear, but
cytomegalovirus (CMV) infection may be a potential cause
in some IBD patients. We carried out a meta-analysis to
investigate the relationship between CMV infection and
steroid-resistant IBD.
Methods The PubMed, EMBASE, and Cochrane Library
databases were searched up to June 2014, with no language
restrictions, for observational studies. Additional refer-
ences were obtained from reviewed articles.
Results Eleven studies involving 867 IBD patients were
included in the meta-analysis. Steroid resistance rate was
70.0 % in CMV-positive IBD patients, which was sig-
nificantly higher than that in CMV-negative IBD patients
(RR = 2.12, 95 % CI = 1.72–2.61). There was significant
heterogeneity in the included eleven studies (I2 = 57.6 %).
When the only one study with a few patients was excluded,
sensitivity analysis suggested a similar outcome
(RR = 2.07, 95 % CI = 1.80–2.39, 10 studies). Based on
the funnel plot and Egger’s test, we considered that there
was a probable publication bias.
Conclusion Our meta-analysis suggests that CMV-posi-
tive IBD patients have a nearly double risk of steroid re-
sistance compared with CMV-negative IBD patients,
indicating that CMV infection is a probable cause of ster-
oid-resistant IBD.
Keywords Cytomegalovirus  Inflammatory bowel
disease  Crohn’s disease  Ulcerative colitis 
Meta-analysis
Introduction
Inflammatory bowel disease (IBD) is described by chronic
inflammation of the gastrointestinal tract in genetically
susceptible individuals exposed to environmental risk fac-
tors, which is represented with active and quiescent phases
alternating and leads to an increasing worldwide health
burden [1, 2]. Crohn’s disease (CD) and ulcerative colitis
(UC) are well known as the two primary subtypes of IBD.
These diseases may result in intestinal destructions, com-
plications, and operative interventions [3, 4].
There is still no completely effective medicine for the
treatment of IBD. 5-aminosalicylates are generally the first-
line medical therapy for UC. Although most IBD patients
can obtain remission by 5-aminosalicylates and steroids
administration, approximately 16–30 % of UC patients and
16–20 % of CD patients are resistant to steroids [5–8], and
steroid-resistant patients may receive anti-TNF therapy or
surgery.
The accurate mechanism of steroid resistance in IBD
patients remains unclear. It is known that immunological
dysfunction of the host, which can be induced by various
pathogens, plays a key role in the development of IBD.
Cytomegalovirus (CMV) is a member of the human
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Herpesviridae family which contains a double-stranded
DNA. CMV can intrude various tissues and organs of the
host, particularly the epithelium of glands and cavities.
Patients with IBD are inclined to have increased risk of
CMV infection [9, 10]. However, the influence of CMV
infection on the prognosis of IBD patients is unclear. Some
studies have showed that anti-CMV treatment can improve
the condition of patients with steroid-resistant IBD [11,
12], but some other trails suggested that antiviral therapy is
not necessary or effective [13–15]. It is still controversial
about whether CMV infection can cause steroid resistance
in IBD patients. For this reason, we performed a meta-
analysis to further investigate the association between
CMV infection and steroid-resistant IBD patients.
Methods
Inclusion/Exclusion Criteria
Studies in line with the following criteria were included:
(a) investigated the prevalence of CMV infection in IBD
patients; (b) presented the outcome of steroid treatment;
and (c) included a control group. Studies were excluded if:
(a) they used data from a previously published study;
(b) they included patients are under 18 years and pregnant;
and (c) they are case reports or case series.
Search Strategy
We performed a search of the PubMed, EMBASE, and
Cochrane Library up to June 2014. A search strategy was
constructed by using a combination of the following words:
(cytomegalovirus or CMV) and (IBD or ulcerative colitis
or Crohn’s disease). Articles published in any language
were included. A manual search of the references listed by
studies retrieved from the online databases and from pre-
viously published systematic reviews was also performed
to identify further relevant studies.
Data Extraction
Two investigators (XW Wu and L Wu) extracted data. Any
differences about study inclusion, data extraction, and in-
terpretation were resolved by consensus before the final
analysis. Study variables were gathered in the following
categories: the year of publication, the country of origin,
the study center, the characteristics of patients, CMV de-
tection method, and definitions of steroid resistance. To
avoid the inclusion of duplicated data in final analysis,
retrieved studies were carefully evaluated and checked by
comparison of author names, geographical locations, and
period of study.
Statistical Methods
Meta-analysis was carried out by combining the risk ratio
(RR) between the CMV-positive groups and CMV-nega-
tive groups of the individual studies in a global RR. Sta-
tistical heterogeneity test was performed by using the Chi-
square and I2 statistics, and I2 value of more than 50 % was
considered to have substantial heterogeneity [16]. A ran-
dom-effects model was selected when the heterogeneity
test showed I2 value of more than 50 %; otherwise, a fixed-
effects model was used. Funnel plot was used as an indi-
cator of publication bias [17]. The Stata version 12.0
software (Stata Corporation, College Station, TX, USA)
was used for all data analysis.
Results
Search Results
Our search identified 431 potentially relevant studies, of
which 398 were excluded after title and abstract screen-
ing. Thirty-three articles were retained for full-text re-
view. Seven review articles, four case reports, eight
studies without outcome of steroid treatment, and three
studies with incomplete data were excluded subsequently.
Finally, we identified eleven studies that fulfilled the in-
clusion criteria [12, 18–27]. These studies included a total
of 867 cases of IBD. Figure 1 shows the study flow
diagram.
Characteristics of Included Studies
The characteristics of included studies and patients are
presented in Table 1. Four studies came from Asia, four
Studies excluded on the basis of title 
and abstract (n=398)  
Studies retrieved for evaluation (n=33) 
Studies eligible for inclusion (n=11) 
Excluded (n=19)  
Reviews (n=7) 
Case reports (n=4) 
No steroid treatment outcome (n=8) 
Incomplete date (n=3) 
Studies identified in search (n=431) 
Fig. 1 Flow diagram of the study selection process
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studies came from Europe, two studies came from Amer-
ica, and one study came from Africa. Ten of them were
single-center studies, and only one was multicenter study.
The mean age of IBD patients ranged from 33 to
44.9 years. Five studies used histopathological tests, four
studies used a combination of serologic and histopatho-
logical tests, and two studies used a combination of PCR
and histopathological tests.
CMV Infection and Steroid-Resistant IBD
When involving all studies including 867 IBD patients, a
total of 70.0 % of patients in the CMV-positive groups were
observed with steroid resistance, compared with 34.5 % of
patients in the CMV-negative groups. The pooled RR of
steroid resistance rate in CMV-positive groups compared to
CMV-negative groups was 2.12 (95 % CI = 1.72–2.61,















CMV detection Definition of steroid resistance
[18] Japan P S 39 40 UC 16 31 Serology,
histopathology
No tendency to improvement even
when prednisone was administered
at a daily dose of 30 mg or more
for at least 2 weeks
[20] USA R S 37 NR UC 11 69 Histopathology Absence of response to systemic
steroids administered for a period
of 2 or more weeks




i.v. for 5–10 days
[21] Italy P S 44.9 43 UC 17 60 Histopathology Chronically active UC with poor
response to medium–high dose of
steroids for more than 2 weeks
[22] Japan R S 33 NR UC 14 8 Histopathology Patients showing no tendency toward
improvement, even when
prednisolone was administered at a
daily dose of 30 mg or more for at
least 2 weeks
[24] Egypt P S 37 43 UC/CD 9 45 Serology,
histopathology
NR
[23] China R S 44.5 50 UC 11 65 Histopathology Resistant to intravenous
hydrocortisone 100 mg three times
daily for 5–7 days
[26] France P S 43.6 90 UC 16 26 Histopathology,
PCR
Persistence of a Lichtiger score
above 7 for moderate UC and
Lichtiger Index score C10 and/or a
decrease\3 for severe UC
(corticosteroids administered at a
dose of 1 mg/kg for 7 days)
[25] Italy P S NR 59 UC 28 57 Histopathology,
PCR
NR
[12] Korea P M 43 67 UC 31 41 Serology,
histopathology
Absence of clinical improvement
after a 7- to 14-day course of
intravenous steroid administration
[27] USA R S NR 37 UC/CD 68 202 Histopathology Minimal or no improvement in
symptoms after 14 days of oral
corticosteroids, 7 days of
intravenous corticosteroids
P prospective, R retrospective, S single center, M multicenter, IBD inflammatory bowel disease, UC ulcerative colitis, CD Crohn’s disease, NR
not reported
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P\ 0.00001). A random-effects model was used for the
meta-analysis because there was significant heterogeneity in
the included studies (I2 = 57.6 %). The result is shown in
Fig. 2.
Subgroup and Sensitivity Analysis
Subgroup analysis of studies according to race of subjects,
CMV detection method, and definition of steroid resistance
is summarized in Table 2. In sensitivity analysis, when the
only one study with a few patients was excluded, significant
association between CMV infection and steroid-resistant
IBD was found either (RR = 2.07, 95 % CI = 1.80–2.39,
P\ 0.00001, 10 studies).
Publication Bias
We found that inspection of the funnel plot did not reveal a
reasonably symmetrical distribution of included studies on
the association between CMV infection and steroid-resis-
tant IBD (Fig. 3). The Egger’s linear regression method
also suggested a statistical evidence of publication bias
(P = 0.016). Accordingly, we considered that there was a
probable bias for publication.
NOTE: Weights are from random effects analysis
Overall  (I-squared = 57.6%, p = 0.009)
Criscuoli et al. 2004
Criscuoli et al. 2011
McCurdy et al. 2014
ID
Li et al. 2009
Maconi et al. 2005
Study
Maher et al. 2009
Kuwabara et al. 2007
Kambham et al. 2004
Roblin et al. 2011
Wada et al. 2003





























Fig. 2 Forest plot of steroid resistance rate in CMV-positive groups versus CMV-negative groups
Table 2 Subgroup analyses of pooled relative risks
Characteristics Subgroup N (Study) N (Subject) RR 95 % CI I2 (%)
All 11 867 2.12 1.72–2.61 58
Race of subjects White 7 650 1.94 1.52–2.47 64
Yellow 4 217 2.79 1.96–3.97 0
CMV detection Histopathology 5 525 1.93 1.45–2.57 65
Serology, histopathology 4 215 2.56 1.81–3.62 0
Histopathology, PCR 2 127 2.29 0.93–5.62 86
Steroid resistance definition Steroid given for C2 weeks 4 226 2.03 1.29–3.19 75
Steroid given for\2 weeks 5 502 1.99 1.64–2.43 0
Not reported 2 139 3.17 2.11–4.76 0
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Discussion
The relationship between CMV and IBD was first described
in 1961 [28]. From that time, the real pathological and
clinical consequences of CMV infection have been debated
for years, and the role of CMV infection in patients with IBD
is not confirmed yet. It is conflicting about whether CMV
reactivation aggravates the inflammation in patients with
established IBD or is merely a sequel of IBD activity [29]. A
prospective study found that CMV infection was rare with a
rate of 4.5 % in new-onset UC patients, which suggested that
immunosuppressive medications may be an important risk
factor for CMV infection [30]. The existing studies are in-
terpreted with limitation due to the retrospective design,
insufficient subject, varied diagnostic methods of CMV de-
tection, and even different classifications of disease severity.
Two previous systematic reviews provided important in-
formation regarding the role of CMV in steroid-resistant IBD
[31, 32]. Using strict inclusion and exclusion criteria, our
analysis included five additional studies. Furthermore, we
conducted forest plot and subgroup analysis to get the pooled
RR, and our results showed a positive correlation between
CMV infection and steroid resistance in IBD patients.
The association between CMV infection and steroid
resistance is always simply considered as a marker for
higher viral reactivation rates in immunocompromised
patients. But a meta-analysis involving individual patient
data indicated that CMV colitis may occur in apparently
immunocompetent patients [33]. Although whether CMV
infection causes steroid resistance in patients with IBD is
still uncertain, there are some probable mechanisms that
can explain this phenomenon. CMV might induce mal-
function of T lymphocytes and increase the secretion of
interferon gamma and tumor necrosis factor alpha, which
can exasperate inflammatory reaction [34]. Furthermore,
CMV can induce the expression of cyclooxygenase-2
through EGFRK, Raf, MEK1/2, and ERK1/2 pathway,
which plays a key role of worsening the inflammation [35].
In our meta-analysis, the pooled RR in CMV-positive
groups versus CMV-negative groups was 2.12 (95 %
CI = 1.72–2.61), which suggested that CMV infection
might lead to a nearly double risk of steroid resistance in
IBD patients. Although the exact direction of causal rela-
tionship between CMV and IBD is hard to establish, it is
necessary to focus on the potential effect of CMV aggra-
vating the inflammation. Furthermore, association between
antiviral treatment and a favorable outcome was demon-
strated in some included studies, which may enhance the
evidence of CMV infection as a possible cause of steroid-
resistant IBD. Wada et al. [18] found that after adminis-
tration of ganciclovir for 14 days, eight of the twelve UC
patients infected with CMV showed resolution of symp-
toms and improved endoscopic features. Kim et al. [12]
reported that the CMV infection was more frequent in
steroid-refractory UC, and patients with CMV infection
had a higher dose of steroids used during the flare-up pe-
riod. Of the fourteen steroid-refractory UC patients with
CMV infection, eleven patients improved with ganciclovir
treatment, and only three patients underwent surgery be-
cause of a lack of response.
Our meta-analysis shows that CMV may be a probable
cause of steroid-resistant IBD. However, the results of the
meta-analysis are limited. Firstly, most studies are retro-
spective. Secondly, there have been some differences in the
method of CMV detection and definition of steroid resis-
tance. Furthermore, there may be a potential publication
bias. Therefore, the finding should be interpreted cau-
tiously, and more multicenter prospective studies are re-
quired to confirm the results of this meta-analysis.
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